A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization

Cervical Intraepithelial Neoplasia Clinical Trial

Official title:

A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03745846
• Other study ID #: CIN-HPV-001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 2018
• Est. completion date: December 2019

Study information

• Verified date: November 2018
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: wen xin Liu, MD?PHD
• Phone: 022-23340123
• Email: wenxin1973[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of composite gel containing black raspberry extract in removing HPV From patients With cervical intraepithelial neoplasia(CIN) after cervical conization

Description:

A large number of basic research and animal experiments have confirmed that black raspberry and its active ingredients are used for chemo-prevention of tumors. In recent years, it has been reported that black raspberry extract can effectively inhibit the proliferation of human oral cancer cells and colorectal cancer cells and promote its apoptosis. At the same time, studies have found that chemically modified lactoglobulin exhibits highly potent antiviral activity against human papillomavirus (HPV) infection, including HPV6, HPV16 and HPV18, and can be used as an effective and safe antiviral drug for treatment and Prevent HPV infection. This study attempts to apply black raspberry and lactoglobulin to remove HPV virus and prevent cervical cancer, in order to make breakthroughs in the prevention and control of cervical cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 78
• Est. completion date: December 2019
• Est. primary completion date: August 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subjects were able and willing to sign informed consent.

• Patients with CIN who underwent cervical conization were at high risk of persistent HPV infection.

• Age must be between 20-55 years old.

• Subjects should begin receiving protocol studies at least two months after cervical conization.

• Patients must be readily available for study and follow-up.

• Patients should not participate in other clinical trials at the same time and agree not to participate in other interventional clinical trials during the protocol study. Except for questionnaires or observational studies.

• Patients should have appropriate nutritional status: body mass index BMI = 18 kg / m2, body weight > 40 kg, serum albumin = 3 g / dL.

Exclusion Criteria:

Anyone who meets any of the following criteria is not allowed to participate in this test:

• Pregnant women, pregnant and lactating women.

• Patients who participated in other clinical trials in the past 3 months.

• It has a serious primary disease such as cardiovascular and cerebrovascular, hematopoietic system and liver and kidney, or patients with mental illness.

• Allergic patients.

• People with epidemics such as AIDS.

• Suffering from uncontrolled complications, including but not limited to: persistent or active infection; clinically significant healing or non-healing wounds; symptomatic congestive heart failure; unstable angina; clinically significant arrhythmia; A disease that affects research compliance, such as an infectious disease or a mental illness/social condition.

• Active, uncontrolled bacterial, viral or fungal infections and require systemic treatment.

• The patient has a history of other malignancies or is suffering from malignant tumors and autoimmune diseases.

• Have any active disease that may increase the risk of a program study or impair a patient's ability to receive protocol research.

• Patients who plan to stay on vacation for 14 days or more during the study period.

Related Conditions & MeSH terms

• Carcinoma in Situ
• Cervical Intraepithelial Neoplasia
• HPV
• Neoplasms

Intervention

Biological:
• Composite Gel Containing Black Raspberry
Composite Gel Containing Black Raspberry 3,000/preparation
• placebo
Composite Gel Containing Black Raspberry-placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	negative rate	the effective rate and clearance rate of HPV infection from baseline as compared to placebo	3 months
Secondary	Adverse Events	The Rate of Solicited Adverse Events and the Related Features	3 months
Secondary	recurrence rate	The recurrence rate after HPV clearance was assessed	3 months